Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in Pihlajalinna Plc’s Management Team

Pihlajalinna Plc Stock exchange release  5 May 2022 at 9.10 a.m.   Change in Pihlajalinna Plc’s Management Team   Pihlajalinna is planning the renewal of its operating structure and a transition to an organisational structure based on business activities. The renewal of the operating structure would also lead to a change in Pihlajalinna’s segment reporting. Going forward, the operating segments would be the company’s two business segments: Public Services, and Private Clinic and Hospital Services.Pihlajalinna Group has appointed Eetu Salunen, Licentiate of Medicine and Master

Invitation to presentation of Interim Report January 1 – March 31, 2022

Mekonomen’s Interim Report for the first quarter 2022 will be published on Wednesday 11 May at 07:30 a.m CEST. A webcast/telephone conference will be held on the same day at 09:00 a.m CEST in English. Mekonomen's President and CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English speaking conference. The presentation material will be available from 8:00 a.m CEST on 11 May, at www.mekonomen.com under the heading Investors/IR Presentations.  

Enhertu approved in US for 2L HER2+ breast cancer

05 May 2022 07:10 BST Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or

Interim Report First Quarter 2022

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2022 – 31.03.2022. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:When we look back on Q1 2022 it was gratifying to see the hard work of 2021 successfully completed: We had a medical cannabis oil product approved for Denmark, we entered the UK market with three approved

BioStock: Sprint Bioscience launches NIMA at BIO International

It has been a little more than six months since Huddinge-based Sprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16. BioStock contacted Martin Andersson, CSO at Sprint Bioscience, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-launches-nima-at-bio-international/This is a press release from BioStock - Connecting

Farxiga HFpEF Phase III trial met primary endpoint

5 May 2022 07:05 BST Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Results from the DELIVER and DAPA-HF Phase III trials demonstrate Farxiga's efficacy in heart failure regardless of ejection fraction High-level results from the DELIVER Phase III trial showed AstraZeneca's Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

Ultomiris NMOSD Ph. III trial met primary endpoint

5 May 2022 07:00 BST Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder Zero adjudicated relapses observed among Ultomiris patients over a median treatment duration of 73 weeks   Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the

Aiforia Technologies Plc appoints Vice President of Sales for Europe

Aiforia Technologies Plc, Press Release, 5 May 2022 at 09.00 a.m. EEST. Incoming Vice President joins Aiforia from global market leader in digital pathology devices, 3DHISTECH, bringing with him decades of experience holding various executive positions in sales at other companies such as Cisco and Ericsson.Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical

AutoStore: Reminder - invitation to presentation of first quarter 2022 financial results

(Oslo, 5 May 2022): AutoStore Holdings Ltd (AutoStore: OSE:AUTO) invites investors, analysts and journalists to join the presentation of the first quarter 2022 financial results on Thursday 12 May 2022 at 08:00 CEST via a live webcast and conference call.06:00 - Announcement of first quarter 2022 financial results. All material will be made available on newsweb.no and www.autostoresystem.com. 08:00 - Presentation will be held only via live webcast and conference call. The presentation will be hosted by Karl Johan Lier, CEO, Bent Skisaker, CFO, and Mats Hovland Vikse, CRO. It will be

Citycon among Financial Times’ European Climate Leaders for the second consecutive year

CITYCON OYJ Corporate Press Release 5 May 2022 Citycon is among Europe’s Climate Leader companies according to Financial Times and German research company Statista. Citycon is the only Finnish real estate company included on the list and is in the top quarter of all European companies regardless of the sector. “We are proud to be recognized among the Climate Leaders for the second consecutive year. This acknowledgement provides evidence of the hard work done by Cityconners to implement targeted measures to reduce greenhouse gas emissions”, says F. Scott Ball, the Chief

Metsä Group awarded as Finland’s most startup-friendly company in 2021

Metsä Group press release 5 May 2022Metsä Group has been selected as the most startup-friendly company in Finland in 2021. The award is presented by the entrepreneurial and startup community Tribe Tampere. "Metsä Group has actively developed its cooperation with the startup field, most concretely by establishing the innovation company Metsä Spring about four years ago. We are very grateful and proud that our determined contribution has led to this recognition,” says Erik Kolehmainen, who is responsible for Corporate Venturing operations at Metsä Group. Selection criteria for the award

DDM Holding AG and DDM Debt AB to report first quarter 2022

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2022 reports on Thursday 19 May 2022 at 08:00 CEST. Mr. Florian Nowotny, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 427 06Switzerland: +41 225 805

DDM Holding AG and DDM Debt AB to report first quarter 2022

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2022 reports on Thursday 19 May 2022 at 08:00 CEST. Mr. Florian Nowotny, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 427 06Switzerland: +41 225 805

I-Tech AB (publ) Interim report Q1 2022

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the first quarter 2022 Click here on the 5 May 2022 at 10:30 to follow the webcast  Click here to go to I-Tech's Financial Reports Summary of the period ” Increased profit and improved profitability in a quarter with unchanged net sales ” • Net turnover for the first quarter amounted to 14 478 (14 458) kSEK, corresponding to an increase in turnover of 0% (7%). Operating profit/loss amounted to 333 (58) kSEK.

Interim report Q1 2022

Growth despite challenging conditionsFirst quarter, January-March, 2022 · Operating revenue was SEK 2,147 million (1,986), an increase of 8.1 percent, which is mainly explained by acquisitions, previously opened units within Elderly Care, and strong growth in Norway. · Organic growth was 1.8 percent (2.4). Organic growth was driven by Elderly Care and Norway, but growth was slowed down by lower occupancy and closed units within Individual and Family. · Operating profit amounted to SEK 77m (112), a decline of 31.9 percent. The decrease is partly explained by externally related

AcadeMedia’s interim report July 2021 – March 2022

Third quarter (January – March 2022) · Net sales increased by 5.9 percent and amounted to SEK 3,802 million (3,591). Organic growth, including bolt-on acquisitions, was 4.7 percent. · Operating profit (EBIT) amounted to SEK 313 million (346). · Adjusted operating profit, adjusted for items affecting comparability and effects of IFRS 16, amounted to SEK 264 million (279). Items affecting comparability amounted to SEK -27 million (6) and related to a fire in a compulsory school in the first quarter and restructuring expenses in the Upper Secondary School Segment. · Net profit

Finnair Traffic Performance in April 2022

Finnair Plc                Investor News              5 May 2022 at 9:00 a.m. EEST Clear improvement in April passenger traffic figures year-on-year and even month-on-month despite the Russian airspace closure; cargo figures remain strong In April, Finnair carried 680,300 passengers, which was 740.4% more than in April 2021. The number of passengers in April 2022 was 10.7% more than in March 2022 (month-on-month figures are not fully comparable as there was one fewer day in April). The COVID-19 impact, including the strict travel restrictions imposed by several countries due to the

Bioretec has submitted a market authorization request for its bioresorbable RemeOs™ magnesium screw in the U.S.

Bioretec Ltd    Company Announcement      5 May 2022 at 9.00 a.m. EEST INSIDE INFORMATIONBioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted a De Novo request for market authorization in the United States for the RemeOs™ trauma screw based on bioresorbable magnesium alloy. Bioretec estimates the market authorization in the United States to be granted during the second half of 2022. The previously communicated estimate was in the first half of 2022. The De Novo request provides a registration pathway for novel medical devices for which there is no predicate

Relais Group Plc has acquired the remaining shares in SEC Scandinavia A/S and TD Tunga Delar Sverige AB

Relais Group Plc, Company Release 5 May 2022 at 9.00 a.m. EET Relais Group Plc has decided to use the right to purchase the remaining 30 percent of shares in SEC Scandinavia A/S and 4.75 percent of shares in TD Tunga Delar Sverige AB from the minority shareholders. The purchase price of the remaining shares paid in cash was DKK 3.0 million for the shares of SEC Scandinavia A/S and SEK 26.4 million for the additional consideration and shares of TD Tunga Delar Sverige AB. The transactions were completed on 5 May 2022. The 70 percent majority stake in SEC Scandinavia A/S and 95.25

Interim report January–March 2022

Growth remains strong for John MattsonIn first quarter of the year, John Mattson’s growth in income from property management per share amounted to 136%. Adjusted for non-recurring items in 2021, income from property management per share increased 70%. Growth in net asset value (NAV) per share was 36%. Property value increased SEK 1 billion in the first quarter and amounted to SEK 16.9 billion at the end of March. “Our successful acquisitions in 2021, in combination with the value created through management and project activities, are generating continued growth. The expanded property

Interim Report January – March 2022

Highlights Financial highlights · Streaming revenue up 35% from Q1 2021 to 699 (517) MSEK, 33% with constant exchange rates · Group Net sales increased by 27% from Q1 2021 to 747 (588) MSEK · Gross profit of 288 (219) MSEK · Gross profit excluding items affecting comparability of 300 (219) · EBITDA of -149 (-28) MSEK equaling a -19.9% (-4.8%) margin · EBITDA excluding items affecting comparability of -33 (-28) MSEK equaling a -4.4% (-4.8%) margin · Basic and diluted earnings per share amounted to -3.43 (-1.01) SEK · First quarterly report post transition to

MSAB part of new European standard for mobile forensics

MSAB, a global leader in forensic technology for mobile device investigations, has for three years been a part of the EU financed project, ForMobile. ForMobile is a consortium of partners, working in collaboration to create an end-to-end mobile forensic investigation chain, striving to improve digital safety, and security in the EU while respecting fundamental rights. “We are very proud to be the only vendor of digital forensic solutions in the project. MSAB has been a vital part in developing the tools, standard, and training to law enforcement agencies all over EU”, says Joel Bollö, CEO of

Report for the first quarter 2022

Financial and operating highlights 1Q22 (1Q21 in brackets): · Operating revenues were NOK 2 476 million (NOK 1 338 million) · EBITDA was NOK 926 million (NOK 236 million) · EBIT was NOK 681 million (NOK 9 million) · Net result after tax was NOK 430 million (NOK -35 million) Segment highlights 1Q22 (1Q21 in brackets): Renewable Energy · EBITDA NOK 1 220 mill. (NOK 333 mill.) · Continued high power prices · Good wind conditions · Full operation of Högaliden adding 18% generation · Seawind’s JV with Vattenfall was awarded rights to develop the Mara Mohr

Interim Report 1 January – 31 March

Continued good demand and order intakePRESS RELEASE 2022-05-05     FIRST QUARTER The first quarter of the year developed in line with our expectations. Seasonally lower deliveries and increased raw material costs for Wood Protection were largely offset by the result from Sawn Wood and a strong development for Joinery. Demand and order intake for our product areas remained good. For the quarter, EBITDA amounts to SEK 82 million, compared with SEK 65 million the previous year. Net sales for the quarter amounted to SEK 910 million, an increase of 53 percent compared with the

There are no items matching the current filter
There are no more items matching the current filter
Back to top